 |
|
|
|
 |
A Phase II Study of Ertumaxomab in Patients with HER-2-Positive Metastatic Breast Cancer Progressing After Trastuzumab Treatment
[Protocol 07-155]
- Full Title :
- PHASE II STUDY OF THE TRIFUNCTIONAL BISPECIFIC ANTI-HER-2/NEU X ANTI-CD3 ANTIBODY ERTUMAXOMAB IN PATIENTS WITH HER-2/NEU OVEREXPRESSING (3+ OR 2+/FISH+) METASTATIC BREAST CANCER PROGRESSING AFTER TRASTUZUMAB TREATMENT
- Purpose :
Trastuzumab is an antibody used to treat breast cancer in women whose tumors produce excess amounts of the HER2 protein. HER2 is a protein found on the surface of certain cancer cells and can make the cells divide and grow. In some of these women, however, the cancer stops responding to trastuzumab and continues to grow.
The purpose of this study is to evaluate the safety and effectiveness of ertumaxomab, another type of monoclonal antibody that targets HER2, in women with metastatic breast cancer that no longer responds to trastuzumab. Antibodies are proteins that are part of the immune system and are important in defending the body against foreign substances. By bringing immune cells and cancer cells together, researchers hope to kill more cancer cells this way.
- Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have HER2-positive metastatic breast cancer that no longer responds to trastuzumab.
- Patients must not be confined to a bed or chair for more than half of their normal waking hours.
- Patients must be age 18 or older.
For more information and to inquire about eligibility for this study, please contact Dr. Shanu Modi at 646-888-5243.
|
|
|
|
|
